Tagged with Vaccines,

Opinion Airfinity’s Dr Patricia Gallego highlights the persistent threat that COVID-19 continues to present to patients and healthcare systems around the world and outlines the urgent need for more vaccine breakthroughs in 2023 to combat the “tripledemic” burden of COVID-19, flu and RSV.   2023 will be a pivotal year for…

Africa The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one here) from Lenias Hwenda of Medicines for Africa. Here, Hwenda shines a light on the importance of preventing mother-to-child transmission…

LatAm As the COVID-19 pandemic showed, vaccines are humanity’s best weapon in the fight against infectious diseases. Nowhere is this more evident than Latin America, where specific climatic, geographic, and social conditions combine to create a propensity for the spread of diseases like dengue and chagas.   With most countries in…

Global IFPMA Director General Thomas Cueni highlights the global innovative pharmaceutical industry’s five key priorities for ensuring better national and international healthcare responses to future pandemics, drawing on the lessons of COVID-19.   The international community is working to rebuild the global health architecture to ensure it is fit for purpose…

Global Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV), which has seen a major spike in cases this winter. Linley assesses the potential impact of some major new treatments…

South Africa Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as 70 to 90 percent of the medicines consumed there. As the COVID-19 pandemic further demonstrated this dependence and the vulnerability…

Saudi Arabia The latest news from the Saudi healthcare and life science industry, including how the implementation of COVID-19 measures have helped reduce the prevalence of MERS-CoV in the country, regulatory approval for Alvotech and Bioventure’s Humira biosimilar, and Open Medical’s new partnership with Tamer Group around digital transformation solutions.   As…

Global For a  biotech that had never before brought a drug to market, Moderna’s COVID-19 vaccine was a revelation. Not only did the vaccine validate the company’s focus on mRNA technology, it also led to huge profits, namely a net income of USD 12.2 billion in 2021 and vaccine sales adding…

China One of China’s leading vaccine manufacturers, CanSino Biologics has taken massive strides since its foundation in 2009 and has secured approvals in several countries for its ebola, meningitis, and COVID-19 jabs. The manufacturer of the world’s first inhaled COVID-19 vaccine, CanSinoBIO is also continuing to invest in mRNA technology in…

China A roundup of some of the biggest healthcare and pharma news from China including the exclusion of Pfizer’s Paxlovid from the country’s national insurance coverage, CanSino’s promising mRNA booster trial results, WuXi Biologics and GSK’s T-cell engager deal, Biocytogen and Hansoh’s antibody collaboration …   Pfizer CEO rules out generic…

Africa Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the European Medicines Agency, and its progress thus far. Hwenda also examines how the AMA stands to impact Africa’s clinical trial…

Global After gaining its first global approval in Indonesia, Takeda’s dengue fever vaccine, Qdenga, recently got a green light from the European Commission (EC) to market the vaccine in Europe, laying the foundation for further approvals in dengue-endemic regions like Latin America. We are one step closer to achieving our aspiration…